Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net loss	$ (6,248)	$ (11,225)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of deferred financing costs	893	465
Depreciation, amortization and accretion	14,572	2,735
Stock-based compensation expense	1,107	0
Change in fair value of interest rate swaps	3,362	594
Gain on extinguishment of debt	(6,261)	0
Unrealized gains on foreign currency, net	11,439	0
Deferred tax benefit	(1,175)	970
Changes in assets and liabilities:
Accounts receivable	661	(1,037)
Prepaid expenses and other current assets	7,254	(17)
Accounts payable, accrued expenses, and other current liabilities	(12,507)	(4,760)
Due to/from SunEdison, net	2,553	11,595
Other noncurrent assets and liabilities	0	2,054
Net cash (used in) provided by operating activities	(7,228)	1,374
Cash flows from investing activities:
Capital expenditures	(33,231)	(60,050)
Change in cash committed for construction	0	7,734
Change in restricted cash	44,539	819
Cash paid for acquisitions, net of cash acquired	0	(137)
Deposits on investments	0	(860)
Cash acquired upon FERSA consolidation	9,031	0
Returns from BioTherm escrow and deposits	3,775	0
Net cash provided by (used in) investing activities	24,114	(52,494)
Cash flows from financing activities:
Repayments of the 2022 Senior Notes	35,441	0
Proceeds from system debt financing	0	40,392
Repayments of system debt financing	(2,705)	(3,607)
Net SunEdison investment	45,991	2,916
Dividends paid	(30,674)	0
Payment of deferred financing costs	0	(1,752)
Net cash (used in) provided by financing activities	(22,829)	37,949
Net decrease in cash and cash equivalents	(5,943)	(13,171)
Effect of exchange rate changes on cash and cash equivalents	5,135	(617)
Cash and cash equivalents at beginning of period	922,318	150,146
Cash and cash equivalents at end of period	$ 921,510	$ 136,358